New therapeutic targets in the inflammatory microenvironment

Por Tartour, Eric
Publicado no ESMO Open (2018)

Widespread rash in lung adenocarcinoma

Por Gálvez-Montosa, Fernando, Jurado, José Miguel, Almazan, Francisco
Publicado no ESMO Open (2018)

2017 Thank you to our reviewers

Publicado no ESMO Open (2018)

Abiraterone: moving up in line?

Por Strijbos, Michiel
Publicado no ESMO Open (2018)

Recent advances in adjuvant therapy for patients with melanoma

Por Weber, Jeffrey
Publicado no ESMO Open (2018)

Extrapolation concept at work with biosimilar: a decade of experience in oncology

Por Krendyukov, Andriy, Schiestl, Martin
Publicado no ESMO Open (2018)

In the literature: April 2018

Por Gambardella, Valentina, Bruixola, Gemma, Cervantes, Andrés
Publicado no ESMO Open (2018)

New data: new options for front-line therapy in NSCLC?

Por Reinmuth, Niels
Publicado no ESMO Open (2018)

Neoadjuvant treatment: the future of patients with breast cancer

Por Reyal, F, Hamy, AS, Piccart, Martine J
Publicado no ESMO Open (2018)

In the literature: June 2018

Por Pérez-Fidalgo, José Alejandro, Gambardella, Valentina, Cervantes, Andrés
Publicado no ESMO Open (2018)

Questions asked in the everyday practice: immune checkpoint inhibitors

Por Haanen, John B A G
Publicado no ESMO Open (2018)

Patient-reported outcomes in a phase II study of alectinib

Por Ohe, Yuichiro
Publicado no ESMO Open (2018)

Macrophage repolarisation therapy in colorectal cancer

Por Halama, Niels
Publicado no ESMO Open (2018)

Epigenetic biomarkers in cancer

Por Egger, Gerda
Publicado no ESMO Open (2018)

In the literature: August 2018

Por Gambardella, Valentina, Martin-Martorell, Paloma, Cervantes, Andrés
Publicado no ESMO Open (2018)

Cancer and the arts: a Pacifist’s Guide to the War on Cancer

Por Wagner, Wolfgang
Publicado no ESMO Open (2018)

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor

Por Koo, Dong-Hoe, Ryu, Min-Hee, Kim, Kyoung-Mee, Yang, Han-Kwang, Sawaki, Akira, Hirota, Seiichi, Zheng, Jie, Zhang, Bo, Tzen, Chin-Yuan, Yeh, Chun-Nan, Nishida, Toshirou, Shen, Lin, Chen, Li-Tzong, Kang, Yoon-Koo
Publicado no Cancer Res Treat (2016)

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy

Por Dolly, Saoirse O, Migali, Cristina, Tunariu, Nina, Della-Pepa, Chiara, Khakoo, Shelize, Hazell, Steve, de Bono, Johann S, Kaye, Stanley B, Banerjee, Susana
Publicado no ESMO Open (2017)

Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?

Por Grössmann, Nicole, Wild, Claudia
Publicado no ESMO Open (2017)

Is CBOP/BEP an alternative to BEP for patients with poor prognosis metastatic germ cell tumours?

Por Addeo, A, Fusco, V, Braybrooke, JP
Publicado no ESMO Open (2016)